U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H23N3O5.ClH
Molecular Weight 457.907
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOPOTECAN HYDROCHLORIDE

SMILES

Cl.CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C3N=C5C=CC(O)=C(CN(C)C)C5=C4)C2=O

InChI

InChIKey=DGHHQBMTXTWTJV-BQAIUKQQSA-N
InChI=1S/C23H23N3O5.ClH/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20;/h5-8,27,30H,4,9-11H2,1-3H3;1H/t23-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C23H23N3O5
Molecular Weight 421.4458
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020671s021lbl.pdf

Topotecan, a semi-synthetic derivative of camptothecin (a plant alkaloid obtained from the Camptotheca acuminata tree), is an anti-tumor drug with topoisomerase I-inhibitory activity similar to irinotecan. DNA topoisomerases are enzymes in the cell nucleus that regulate DNA topology (3-dimensional conformation) and facilitate nuclear processes such as DNA replication, recombination, and repair. During these processes, DNA topoisomerase I creates reversible single-stranded breaks in double-stranded DNA, allowing intact single DNA strands to pass through the break and relieve the topologic constraints inherent in supercoiled DNA. The 3'-DNA terminus of the broken DNA strand binds covalently with the topoisomerase enzyme to form a catalytic intermediate called a cleavable complex. After DNA is sufficiently relaxed and the strand passage reaction is complete, DNA topoisomerase reattaches the broken DNA strands to form the unaltered topoisomers that allow transcription to proceed. Topotecan interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells can be affected by the medicine, other effects may also occur. Unlike irinotecan, topotecan is found predominantly in the inactive carboxylate form at neutral pH and it is not a prodrug. Topotecan has the same mechanism of action as irinotecan and is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death). Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor. Topotecan is used for the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy. Topotecan is sold under the trade name Hycamtin.

CNS Activity

Curator's Comment: freely crosses the blood-brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1028.0 nM [IC50]
3.16 µM [IC50]
0.448 µM [IC50]
1.1 µM [IC50]
33.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HYCAMTIN

Approved Use

HYCAMTIN for injection is a topoisomerase inhibitor indicated for: • metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy. • small cell lung cancer platinum-sensitive disease in patients who progressed after first-line chemotherapy. • combination therapy with cisplatin for Stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment.

Launch Date

1996
Primary
HYCAMTIN

Approved Use

HYCAMTIN for injection is a topoisomerase inhibitor indicated for: • metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy. • small cell lung cancer platinum-sensitive disease in patients who progressed after first-line chemotherapy. • combination therapy with cisplatin for Stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.1 ng/mL
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
7.9 ng/mL
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
9.29 ng/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
210.5 nM × h
1.25 mg/m² single, intravenous
dose: 1.25 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
262.7 nM × h
1.5 mg/m² single, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
304.3 nM × h
2 mg/m² single, intravenous
dose: 2 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
379.6 nM × h
1.75 mg/m² single, intravenous
dose: 1.75 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
49.3 ng × h/mL
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
60.7 ng × h/mL
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
61 ng × h/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
1.25 mg/m² single, intravenous
dose: 1.25 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.7 h
1.5 mg/m² single, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.7 h
2 mg/m² single, intravenous
dose: 2 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.5 h
1.75 mg/m² single, intravenous
dose: 1.75 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6 h
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
5.6 h
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
5.23 h
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
22.2%
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
14.8%
2.3 mg/m² single, oral
dose: 2.3 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
65%
TOPOTECAN plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 1, 1 patient)
Leukopenia (grade 2, 1 patient)
Leukopenia (grade 3, 7 patients)
Leukopenia (grade 4, 2 patients)
Neutropenia (grade 2, 6 patients)
Neutropenia (grade 3, 2 patients)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 1, 2 patients)
Thrombocytopenia (grade 2, 1 patient)
Thrombocytopenia (grade 3, 1 patient)
Thrombocytopenia (grade 4, 2 patients)
Anemia (grade 1, 3 patients)
Anemia (grade 2, 3 patients)
Anemia (1 patient)
Sources:
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 1, 4 patients)
Leukopenia (grade 2, 4 patients)
Leukopenia (grade 3, 3 patients)
Leukopenia (grade 4, 1 patient)
Neutropenia (grade 1, 1 patient)
Neutropenia (grade 2, 2 patients)
Neutropenia (grade 3, 1 patient)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 2, 3 patients)
Thrombocytopenia (grade 3, 2 patients)
Anemia (grade 1, 4 patients)
Anemia (grade 2, 1 patient)
Anemia (grade 3, 1 patient)
Anemia (3 patients)
Sources:
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 3, 40.7%)
Leukopenia (grade 4, 15.9%)
Neutropenia (grade 3, 31%)
Neutropenia (grade 4, 50.4%)
Thrombocytopenia (grade 3, 17.7%)
Thrombocytopenia (grade 4, 22.1%)
Anemia (grade 3, 26.5%)
Anemia (grade 4, 2.7%)
Nausea (grade 1, 31.9%)
Nausea (grade 2, 25%)
Nausea (grade 3, 5.2%)
Alopecia (grade 1, 19.8%)
Alopecia (grade 2, 22.4%)
Alopecia (grade 3, 4.3%)
Fatigue (grade 1, 22.4%)
Fatigue (grade 2, 10.3%)
Fatigue (grade 3, 5.2%)
Vomiting (grade 1, 12.1%)
Vomiting (grade 2, 19.8%)
Vomiting (grade 3, 4.3%)
Vomiting (grade 4, 0.9%)
Diarrhea (grade 1, 19%)
Diarrhea (grade 2, 13.8%)
Diarrhea (grade 3, 1.7%)
Diarrhea (grade 4, 0.9%)
Sources:
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (grade 4, 58%)
Sources:
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Other AEs: Thrombocytopenia, Anemia...
Other AEs:
Thrombocytopenia (grade 4, 20%)
Anemia (grade 3-4, 11%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anemia 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 1, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 1, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia grade 1, 3 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 2, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 2, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia grade 2, 3 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 2, 6 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 3, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 3, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 3, 7 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 4, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 4, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 4, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 1, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia grade 1, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 1, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia grade 2, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 2, 2 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 2, 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 2, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Anemia grade 3, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 3, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Thrombocytopenia grade 3, 2 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 3, 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Leukopenia grade 4, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Neutropenia grade 4, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
Health Status: unhealthy
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Sources:
Vomiting grade 1, 12.1%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Diarrhea grade 1, 19%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Alopecia grade 1, 19.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Fatigue grade 1, 22.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Nausea grade 1, 31.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Fatigue grade 2, 10.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Diarrhea grade 2, 13.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Vomiting grade 2, 19.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Alopecia grade 2, 22.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Nausea grade 2, 25%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Diarrhea grade 3, 1.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Thrombocytopenia grade 3, 17.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Anemia grade 3, 26.5%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Neutropenia grade 3, 31%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Alopecia grade 3, 4.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Vomiting grade 3, 4.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Leukopenia grade 3, 40.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Fatigue grade 3, 5.2%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Nausea grade 3, 5.2%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Diarrhea grade 4, 0.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Vomiting grade 4, 0.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Leukopenia grade 4, 15.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Anemia grade 4, 2.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Thrombocytopenia grade 4, 22.1%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Neutropenia grade 4, 50.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
Health Status: unhealthy
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Sources:
Neutropenia grade 4, 58%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Anemia grade 3-4, 11%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Thrombocytopenia grade 4, 20%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
2000 Aug
The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis.
2001
A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3).
2001
Treatment of extensive stage small cell lung cancer.
2001
Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction.
2001
ICE bioassay. Isolating in vivo complexes of enzyme to DNA.
2001
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
2001 Apr
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
2001 Apr
Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
2001 Apr 1
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
2001 Apr 1
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
2001 Apr 15
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
2001 Apr 20
A mutation in subunit B of the DNA polymerase alpha-primase complex from Novikoff hepatoma cells concomitant with a conformational change and abnormal catalytic properties of the DNA polymerase alpha-primase complex.
2001 Aug
Clear cell carcinoma of the ovary: a remarkable case.
2001 Feb
Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393).
2001 Feb
P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.
2001 Feb 1
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
2001 Feb 15
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
2001 Jan
The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer.
2001 Jan
Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.
2001 Jan
Prevention of human smooth muscle cell proliferation without induction of apoptosis by the topoisomerase I inhibitor topotecan.
2001 Jan 1
Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.
2001 Jan 1
Advances in the management of epithelial ovarian cancer.
2001 Jul
Topoisomerase I inhibitors in the treatment of head and neck cancer.
2001 Jul
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.
2001 Jul
UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice.
2001 Jul
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.
2001 Jul 15
Oligodendroglial ganglioglioma with anaplastic features arising from the thalamus.
2001 Jun
Temporary reversal by topotecan of marked insulin resistance in a patient with myelodysplastic syndrome: case report and possible mechanism for tumor necrosis factor alpha (TNF-alpha)-induced insulin resistance.
2001 Jun
Overview of the treatment of infant central nervous system tumors: medulloblastoma as a model.
2001 Jun-Jul
Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice.
2001 Mar
Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells.
2001 Mar
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
2001 Mar 1
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
2001 May
Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
2001 May 15
Patents

Sample Use Guides

Ovarian cancer and small cell lung cancer: 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course. Cervical cancer: 0.75 mg/m2 by intravenous infusion over 30 minutes on Days 1, 2, and 3 repeated every 21 days in combination with cisplatin 50 mg/m2 on Day 1
Route of Administration: Intravenous
In Vitro Use Guide
In DC3F hamster lung fibroblasts, 2.5 uM topotecan caused redistribution of topo I to nonnucleolar regions of the nucleus.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:32:05 GMT 2025
Edited
by admin
on Mon Mar 31 18:32:05 GMT 2025
Record UNII
956S425ZCY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NOGITECAN HYDROCHLORIDE
JAN  
Preferred Name English
TOPOTECAN HYDROCHLORIDE
MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
TOPOTECAN ACTAVIS
Brand Name English
(S)-10-((DIMETHYLAMINO)METHYL)-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE MONOHYDROCHLORIDE
Systematic Name English
1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 10-((DIMETHYLAMINO)METHYL)-4-ETHYL-4,9-DIHYDROXY-, MONOHYDROCHLORIDE, (S)-
Common Name English
EVOTOPIN
Brand Name English
TOPOTECAN HYDROCHLORIDE [USAN]
Common Name English
SK&F S-104864-A
Code English
TOPOTECAN HYDROCHLORIDE [MI]
Common Name English
TOPOTECAN HYDROCHLORIDE [VANDF]
Common Name English
HYCAMTIN
Brand Name English
TOPOTECAN HYDROCHLORIDE [USP-RS]
Common Name English
TOPOTECAN (AS HYDROCHLORIDE)
Common Name English
TOPOTECAN HCL
Common Name English
TOPOTECAN HOSPIRA
Brand Name English
NOGITECAN HYDROCHLORIDE [JAN]
Common Name English
Topotecan hydrochloride [WHO-DD]
Common Name English
POTACTASOL
Brand Name English
NSC-759263
Code English
TOPOTECAN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
SK&F-S-104864-A
Code English
TOPOTECAN TEVA
Brand Name English
TOPOTECAN HYDROCHLORIDE [MART.]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 268508
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
EMA ASSESSMENT REPORTS POTACTASOL (AUTHORIZED: UTERINE CERVICAL NEOPLASMS)
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
EMA ASSESSMENT REPORTS TOPOTECAN TEVA (AUTHORIZED: UTERINE CERVICAL NEOPLASMS)
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
EMA ASSESSMENT REPORTS HYCAMTIN (AUTHORIZED: UTERINE CERVICAL NEOPLASMS)
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
EMA ASSESSMENT REPORTS TOPOTECAN EAGLE (WITHDRAWN SMALL CELL LUNG CARCINOMA)
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
EMA ASSESSMENT REPORTS TOPOTECAN TEVA (AUTHORIZED: OVARIAN NEOPLASMS)
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
EMA ASSESSMENT REPORTS EVOTOPIN (WITHDRAWN: OVARIAN NEOPLASMS)
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
NCI_THESAURUS C2843
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
EMA ASSESSMENT REPORTS TOPOTECAN ACTAVIS (AUTHORIZED: UTERINE CERVICAL NEOPLASMS)
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
EU-Orphan Drug EU/3/08/562
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
EMA ASSESSMENT REPORTS HYCAMTIN (AUTHORIZED: OVARIAN NEOPLASMS)
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
EMA ASSESSMENT REPORTS TOPOTECAN HOSPIRA (AUTHORIZED: UTERINE CERVICAL NEOPLASMS)
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL84
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
DRUG BANK
DB01030
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
RXCUI
266573
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY RxNorm
FDA UNII
956S425ZCY
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
DAILYMED
956S425ZCY
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
PUBCHEM
60699
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
USAN
BB-40
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
RS_ITEM_NUM
1672257
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
CAS
119413-54-6
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
EVMPD
SUB04921MIG
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
NCI_THESAURUS
C2828
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
MERCK INDEX
m10977
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY Merck Index
SMS_ID
100000091113
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
EPA CompTox
DTXSID1045952
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
NSC
759263
Created by admin on Mon Mar 31 18:32:05 GMT 2025 , Edited by admin on Mon Mar 31 18:32:05 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE